GlymaxX®: A Smart Way of Modulating Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
Natural Killer (NK) cell mediated tumor cell killing is one prominent mode of action for anti-cancer or anti-infectious antibodies. It relies on the antibody´s ability to recruit NK cells, which is enhanced when the antibody Fc glycan is devoid of fucose. Rather than knocking out any genes, ProBioGen redirects fucose synthesis by a heterologous enzyme that depletes the fucose pool inside the cell. Such cells produce afucosylated antibodies with up to 100x higher ADCC activity against tumor cells or virus-infected cells.
Our proprietary GlymaxX® technology can be applied to your standard host cell line. Alternatively, we can offer our own optimized GlymaxX host cell line, or even re-engineer existing producer clones.
We use GlymaxX for
- novel antibody projects
- biobetters (ADCC-enhanced originator mAb)
- biosimilar projects (if adjusting a specific fucose level is crucial)
GlymaxX cell lines are stable and compatible with highest titer production processes. The unique advantage of the GlymaxX technology is that a single cell line is sufficient to produce both completely fucosylated or afucosylated antibodies and those with a defined intermediate fucosylation level. We adjust the level via fucose supplementation in the culture medium.
The technology is endorsed by licensees worldwide and applied to antibodies that are currently in clinical studies.
- Unique flexibility with one GlymaxX cell line for both afucosylated mAbs and fucolsyslated mAbs
- Royalty-free, milestone-based business model
- Clinically proven technology
- Fast development (under 10 weeks)